Among 5-year survivors in the tebentafusp arm, 44% received tebentafusp as their only therapy. In contrast, 86% of control ...
Sikander Ailawadhi, MD discusses the positive sentiments on subcutaneous isatuximab from European regulators and patient ...
As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions. The European Medicines Agency’s ...
New in the NCCN guidelines is lurbinectedin [Zepzelca] and atezolizumab [Tecentriq] maintenance. 2 There are other ...
Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a ...
Dr Singh also takes viewers inside the critical—and often underappreciated—role of multidisciplinary collaboration, ...
Dr Nabil Saba emphasizes that while systemic therapy has revolutionized the treatment of anaplastic thyroid cancer (ATC), ...
Early-line data appears encouraging, with MajesTEC-3 complemented by emerging newly diagnosed data showing near-universal ...
Rashmi Chugh, MD, discusses the early outcomes of a trial of ozekibart plus chemotherapy in Ewing sarcoma. Rashmi Chugh, MD, ...
LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA ...
The FDA review of the biologics license application includes data on SC isatuximab as both manual injection and via an ...
To address the limitations of binary pCR classification, Pusztai and colleagues developed the residual cancer burden (RCB) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results